Straits Times Index
3,408.64 +40.74 (+1.21%) Nikkei
40,425.37 +350.68 (+0.88%) Hang Seng
17,875.39 +106.25 (+0.60%) FTSE 100
8,121.20 -45.56 (-0.56%) Bitcoin USD
61,223.93 -1,714.99 (-2.72%) CMC Crypto 200
1,323.66 -20.85 (-1.55%)
PTGX Jan 2025 30.000 call
- PR Newswire
Protagonist Therapeutics Set to Join S&P SmallCap 600
Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
- Insider Monkey
Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To […]
- Simply Wall St.
We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation
Key Insights Protagonist Therapeutics to hold its Annual General Meeting on 20th of June Salary of US$655.2k is part of...
